Compare OPY & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPY | PHAR |
|---|---|---|
| Founded | 1881 | 1988 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1996 | 2020 |
| Metric | OPY | PHAR |
|---|---|---|
| Price | $123.56 | $11.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $38.33 |
| AVG Volume (30 Days) | ★ 87.1K | 20.7K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ 104.71 | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $1,638,071,000.00 | N/A |
| Revenue This Year | N/A | $10.04 |
| Revenue Next Year | N/A | $2.51 |
| P/E Ratio | ★ $205.22 | $3,041.22 |
| Revenue Growth | ★ 14.35 | N/A |
| 52 Week Low | $63.81 | $9.62 |
| 52 Week High | $125.88 | $21.34 |
| Indicator | OPY | PHAR |
|---|---|---|
| Relative Strength Index (RSI) | 63.63 | 42.27 |
| Support Level | $103.03 | $11.03 |
| Resistance Level | N/A | $13.51 |
| Average True Range (ATR) | 3.96 | 0.35 |
| MACD | 0.55 | -0.01 |
| Stochastic Oscillator | 85.20 | 4.72 |
Oppenheimer Holdings Inc conducts activities in the securities industry. The company is involved in retail securities brokerage, investment banking (both corporate and public finance), institutional sales and trading, market-making, research, trust services, and investment advisory and asset management services. The company has two segments: Wealth Management, and Capital Markets. IT generates maximum revenue from Wealth Management Segment which includes commissions and fee income earned on assets under management (AUM), net interest earnings on client margin loans and cash balances, fees from money market funds, custodian fees and other activities. The company generates the majority of its revenue from the Americas, with the rest from Europe, the Middle East, and Asia.
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.